| Document Date: 2014-12-09 06:39:28
Open Document File Size: 1,12 MBShare Result on Facebook
Company Alnylam Pharmaceuticals / AEs / CBC / PhD Alnylam Pharmaceuticals / / Country United States / / Event FDA Phase / / Facility ECG No laboratory AEs / / IndustryTerm Treatment of Hemophilia / / MedicalCondition Antithrombin deficiency / NHP inhibitor hemophilia / C deficiency / FIX FVIII FX FVIIIa FVIIa FVII Hemophilia B / injury / Hemophilia A / Headache / factor Blood clot / Human AT deficiency / SAD / Hemophilia / S deficiency / Disorders / / Organization European Union / / Person Sorensen / / Product SC / AT3 / Volunteers / / Technology laser / Pharmacodynamics / siRNA / /
SocialTag |
2014 ASH Annual Meeting 322. Disorders of Coagulation or Fibrinolysis: Novel Hemostatic Therapies and Assays A Subcutaneously Administered Investigational RNAi Therapeutic (ALN-AT3) Targeting Antithrombin for Treatment o